Watching and learning about early-stage angiosarcoma
Part of Cancer clinical trials.
This study follows patients with angiosarcoma that has not spread and can be removed with surgery. The goal is to learn more about how this rare cancer behaves and how it is best treated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of angiosarcoma (a cancer that starts in the cells lining your blood vessels).
- Your cancer must be in only one place (localized), not spread to other parts of the body.
- Your tumor must be able to be removed with surgery (resectable).
- There are no age limits or restrictions on where the cancer started.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
This trial tests a combination of two drugs—an injected virus that attacks cancer cells and an immunotherapy that helps the immune system fight the cancer—for people with angiosarcoma that has spread or cannot be removed and has not responded to earlier treatments.
This study is watching people whose high-grade osteosarcoma came back in the same bone area (local relapse) after treatment. It helps doctors understand how local relapse happens, so they can improve future care.
This study looks at the medical details and outcomes of people with breast sarcoma. It may help doctors better understand what treatments and factors are linked to different results over time.
This study collects information and archived tumor samples from people with undifferentiated round cell sarcoma to better understand the disease. It may help future diagnoses and treatments by linking lab findings in tumor tissue to clinical outcomes.
This study is a global registry for people with a rare heart cancer called cardiac angiosarcoma. It collects information on treatments and outcomes to help doctors better understand the disease and improve care.
Hear when a new Angiosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.